A phase 1 study found MP0317, a FAP-targeting CD40 agonist, showed tumor-localized CD40 activation, a favorable safety profile, and immune remodeling in advanced solid tumors.
AbbVie raised 2026 revenue and EPS guidance after first-quarter results beat estimates, with Skyrizi and Rinvoq driving growth. Humira erosion continued as neuroscience, oncology and pipeline assets supported the outlook.
Crescent Biopharma dosed the first patient in its ASCEND Phase 1/2 trial of CR-001, a PD-1 x VEGF bispecific antibody for solid tumors. The company also reported Q1 2026 results and outlined pipeline milestones including ADC combination trials expected in the second half of 2026.
The FDA granted fast track designation to SIM0505, a CDH6-targeting antibody-drug conjugate, for platinum-resistant ovarian cancer based on preclinical and early clinical data. A phase 1 trial is currently evaluating the drug in advanced solid tumors, with initial data expected at the 2026 ASCO conference. The company plans to begin dose optimization studies in ovarian cancer patients in Q2 2026.
Dewpoint Therapeutics has initiated a Phase 1a/2a clinical trial for DPTX3186, a first-in-class therapy targeting biomolecular condensates in advanced solid tumors. The drug's development is based on foundational research from Whitehead Institute on cellular organization and gene regulation. The trial represents an early clinical evaluation of condensate-based therapeutics for cancer treatment.
Adagene and Incyte will collaborate on a Phase 1 study combining muzastotug with INCA33890 for MSS colorectal cancer patients, beginning in 2026. The collaboration marks the second instance where Adagene's SAFEbody technology is paired with a PD-1-based bispecific. Muzastotug has shown encouraging response rates in combination with pembrolizumab in previous trials.
Recursion reported Q4 2025 financial results with $754 million in cash providing runway into early 2028. The company achieved clinical validation of its AI platform with REC-4881 showing meaningful polyp reductions in FAP patients and received its fifth Sanofi milestone payment. Full-year revenue reached $74.7 million while net loss widened to $644.8 million.
Zai Lab announced an update on its Phase 1b/2 clinical study of ZL-1310, an experimental drug designed to treat advanced solid tumors with limited treatment options.
Junshi Biosciences reported total revenue of approximately RMB2,498 million in 2025, a 28% increase year-over-year, driven by toripalimab sales growth. Absci Corporation announced it will report fourth quarter and full year 2025 financial results on March 24, 2026.
AbbVie has successfully transitioned from Humira dependence to growth driven by Skyrizi and Rinvoq, while maintaining a 54-year dividend increase streak and expanding its pipeline to roughly 90 programs through strategic acquisitions.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07601334 |
Safety and Activity of HF50 in Patients With Advanced Solid Tumors |
NOT_YET_RECRUITING | PHASE1 |
| NCT07601243 |
Study of GS-2426 in Participants With Advanced Solid Tumors |
NOT_YET_RECRUITING | PHASE1 |
| NCT07596693 |
KXV01 Injection in Patients With Advanced Solid Tumor (Including Osteosarcoma and Sarcoma) |
RECRUITING | PHASE1 |
| NCT07596381 |
FAK Inhibitor in Patients With Advanced Solid Tumors |
NOT_YET_RECRUITING | PHASE1 |
| NCT07593144 |
A Single-Arm, Open-Label Phase Ia/Ib Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of FS-207 in Patients With Advanced Solid Tumors With High Microsatellite Instability (MSI-H) |
NOT_YET_RECRUITING | PHASE1 |
| NCT07591285 |
A Study of SYS6051 in Subjects With Advanced Solid Tumors |
NOT_YET_RECRUITING | PHASE1 |
| NCT07589530 |
Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors |
RECRUITING | PHASE1/PHASE2 |
| NCT07586943 |
SKB118 Injection in Advanced Solid Tumors |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07583771 |
A Phase Ⅰ Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma |
NOT_YET_RECRUITING | PHASE1 |
| NCT07563972 |
Intratumoral Macrophage Exosomes With Mechanobiological Reprogramming for Advanced Solid Tumors |
RECRUITING | PHASE1 |
